Recent progress in therapeutic antibodies for cancer immunotherapy

•There is a heavy focus of clinical cancer research efforts on cancer immunotherapy.•Treatment with checkpoint inhibitors has shown to improve standard of care.•Immune escape mechanisms may involve different immune phenotypes.•Biomarkers include PD-L1 expression, gene signatures, and tumor mutation burden.•New combinations and bi-specific antibody technologies are being developed.